Cedar Hill Associates’s Bristol-Myers Squibb BMY Stock Holding History

Cedar Hill Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,784	Closed	-$209K	–	119
2018 Q2	$209K	Sell	3,784 -58	-2%	-$3.13K	0.04%	149
2018 Q1	$243K	Buy	+3,842	New	+$247K	0.05%	132
2017 Q4	–	Sell	-3,517	Closed	-$224K	–	148
2017 Q3	$224K	Buy	+3,517	New	+$205K	0.04%	140

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cedar Hill Associates's BMY Position: Q3 2018 in Review

Cedar Hill Associates sold out of Bristol-Myers Squibb (BMY) in Q3 2018, closing a stake of 3,784 shares — an estimated $209K sold.

Cedar Hill Associates first reported a position in BMY in Q3 2017 and held it in 3 quarters. The position peaked at $243K in Q1 2018. 1,729 funds tracked by Wall St. Rank hold BMY as of Q3 2018.

Cedar Hill Associates reported no remaining Bristol-Myers Squibb position as of Q3 2018 after selling out during the quarter.
Cedar Hill Associates sold 3,784 Bristol-Myers Squibb shares in Q3 2018, an estimated $209K.
Cedar Hill Associates first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 3 quarters.
Cedar Hill Associates's Bristol-Myers Squibb position peaked at $243K in Q1 2018.
1,729 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2018.

Based on Cedar Hill Associates's 13F filing for Q3 2018, filed 23 Oct 2018.